title: Occult hepatitis B virus infection among Egyptian blood donors.
abstract: OBJECTIVE
  To identify blood donors with occult hepatitis B virus (HBV) infection (OBI) to promote safe blood donation.
  
  
  METHODS
  Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) and human immunodeficiency virus Ab. They were subjected to the detection of alanine aminotransferase (ALT) and aspartate transaminase (AST) and screening for anti-HBV core antibodies (total) by two different techniques; [Monoliza antibodies to hepatitis B core (Anti-HBc) Plus-Bio-Rad] and (ARC-HBc total-ABBOT). Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface (anti-HBs) (ETI-AB-AUK-3, Dia Sorin-Italy). Serum anti-HBs titers > 10 IU/L was considered positive. Quantitative HBV DNA by real time polymerase chain reaction (PCR) (QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L. Also, 265 recipients were included, 34 of whom were followed up for 3-6 mo. Recipients were investigated for ALT and AST, HBV serological markers: HBsAg (ETI-MAK-4, Dia Sorin-Italy), anti-HBc, quantitative detection of anti-HBs and HBV-DNA.
  
  
  RESULTS
  525/3167 (16.6%) of blood units were positive for total anti-HBc, 64% of those were anti-HBs positive. Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples, where 451 (90.6%) confirmed positive. Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample, giving an overall prevalence of 451/3167 (14.2%) for total anti-HBc. HBV DNA was quantified by real time PCR in 52/303 (17.2%) of anti-HBc positive blood donors (viral load range: 5 to 3.5 x 10(5) IU/mL) with a median of 200 IU/mL (mean: 1.8 x 10(4) ± 5.1 x 10(4) IU/mL). Anti-HBc was the only marker in 68.6% of donors. Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8 (1.4-2.4) and 1.4 (1.0-1.9) respectively. Other risk factors as gender, history of blood transfusion, diabetes mellitus, frequent injections, tattooing, previous surgery, hospitalization, Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies. Among anti-HBc positive blood donors, age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8 (1.8-7.9). According to HBV-DNA concentration, positive samples were divided in two groups; group one with HBV-DNA ≥ 200 IU/mL (n = 27) and group two with HBV-DNA < 200 IU/mL (n = 26). No significant difference was detected between both groups as regards mean age, gender, liver enzymes or HBV markers. Serological profiles of all followed up blood recipients showed that, all were negative for the studied HBV markers. Also, HBV DNA was not detected among studied recipients, none developed post-transfusion hepatitis (PTH) and the clinical outcome was good.
  
  
  CONCLUSIONS
  OBI is prevalent among blood donors. Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation.
authors: Zeinab N Said, Enas K Aboel-Magd, Microbiology and Immunology Department, Faculty of Medicine (for Girls), Al-Azhar University, 11511 Cairo, Egypt.
authors: Zeinab N
authors: ZN
authors: Said
authors: Manal H El
authors: MH
authors: Sayed
authors: Iman I
authors: II
authors: Salama
authors: Enas K
authors: EK
authors: Aboel-Magd
authors: Magda H
authors: MH
authors: Mahmoud
authors: Maged El
authors: ME
authors: Setouhy
authors: Faten
authors: F
authors: Mouftah
authors: Manal B
authors: MB
authors: Azzab
authors: Heidi
authors: H
authors: Goubran
authors: Amal
authors: A
authors: Bassili
authors: Gamal E
authors: GE
authors: Esmat
keywords: Hepatitis B surface antigen; Hepatitis B virus; Hepatitis B virus-DNA; Occult hepatitis B virus infection; Total anti-HBc
references: World J Gastroenterol. 2011 Apr 21;17(15):1927-38
references: 21528070
references: J Clin Virol. 2006 May;36 Suppl 1:S56-64
references: 16831695
references: Haematologica. 2007 Dec;92(12):1664-70
references: 18055990
references: Gastroenterology. 2007 Apr;132(4):1287-93
references: 17433322
references: Transfusion. 2006 Nov;46(11):2028-9
references: 17076860
references: Curr Opin Hematol. 2011 Nov;18(6):461-6
references: 21912252
references: Virol J. 2010 Aug 27;7:204
references: 20799931
references: Vox Sang. 2012 May;102(4):285-93
references: 22082342
references: Transfusion. 2007 Jul;47(7):1197-205
references: 17581154
references: Transfus Sci. 1997 Mar;18(1):49-53
references: 10174292
references: Transfusion. 2009 Oct;49(10):2200-7
references: 19538543
references: Transfusion. 2005 Aug;45(8):1242-6
references: 16078908
references: Epidemiol Infect. 2009 Jul;137(7):961-9
references: 19102797
references: Transfus Med. 2008 Feb;18(1):55-61
references: 18279193
references: Hepatology. 2003 Jul;38(1):86-95
references: 12829990
references: Bull World Health Organ. 1999;77(11):923-8
references: 10612888
references: Transfus Med. 2011 Feb;21(1):33-41
references: 20726954
references: J Hepatol. 2009 Oct;51(4):798-809
references: 19615780
references: Vox Sang. 2004 Feb;86(2):83-91
references: 15023176
references: J Med Virol. 2006;78 Suppl 1:S66-70
references: 16622881
references: Blood. 2003 Mar 15;101(6):2419-25
references: 12393691
references: Transfusion. 2009 Oct;49(10):2214-20
references: 19527477
references: J Hepatol. 2008 Oct;49(4):537-47
references: 18602718
references: J Hepatol. 2005 Apr;42(4):480-5
references: 15763333
references: Hepatology. 2006 Dec;44(6):1666-74
references: 17133474
references: J Med Virol. 2009 May;81(5):815-25
references: 19319945
references: J Viral Hepat. 2010 Jan;17(1):1-15
references: 20002296
references: Transfusion. 2001 May;41(5):652-8
references: 11346702
references: J Clin Microbiol. 2003 Jan;41(1):135-43
references: 12517838
references: Blood. 2002 Oct 1;100(7):2637-41
references: 12239179
references: Liver Int. 2009 Apr;29(4):518-24
references: 19192168
references: J Hepatol. 2008 Oct;49(4):652-7
references: 18715666
references: J Viral Hepat. 2011 Oct;18(10):721-9
references: 21914087
references: Swiss Med Wkly. 2008 Mar 8;138(9-10):134-41
references: 18330733
references: Virol J. 2010 Aug 19;7:193
references: 20718994
references: Transfusion. 1979 Nov-Dec;19(6):725-31
references: 230620
references: Int J Epidemiol. 2009 Jun;38(3):757-65
references: 19420088
references: Transfusion. 2001 Sep;41(9):1093-9
references: 11552064
references: Transfusion. 2008 Nov;48(11):2315-22
references: 18647367
references: Transfusion. 2001 Mar;41(3):329-32
references: 11274585
references: Epidemiol Infect. 2005 Aug;133(4):695-9
references: 16050516
references: Vox Sang. 2001;81(2):140
references: 11555478
references: Transfusion. 2008 May;48(5):1001-26
references: 18454738
references: Med Microbiol Immunol. 2007 Dec;196(4):247-52
references: 17503077
references: Transfus Med. 2004 Apr;14(2):97-103
references: 15113374
references: J Hepatol. 2006 Apr;44(4):818; author reply 819
references: 16473431
references: Transfus Med. 2010 Dec;20(6):409-13
references: 20573069
references: Vox Sang. 2008 May;94(4):358-62
references: 18266781
references: Transfusion. 2003 Jun;43(6):788-98
references: 12757531
references: J Clin Virol. 2006 May;36 Suppl 1:S33-44
references: 16831692
references: J Hepatol. 2008 Jun;48(6):1022-5
references: 18436328
references: Transfusion. 2009 Aug;49(8):1621-9
references: 19413737
references: Rev Saude Publica. 2003 Jun;37(3):339-44
references: 12792685
references: Gut. 2012 Dec;61(12):1744-53
references: 22267593
references: J Clin Virol. 2005 Dec;34 Suppl 1:S15-21
references: 16461218